New HIV/AIDS Topic: Persons Aged 50 and Over
The number of persons aged 50 years and older living with HIV/AIDS has been increasing in recent years. This increase is partly due to highly active antiretroviral therapy (HAART), which has made it possible for many HIV-infected persons to live longer, and partly due to newly diagnosed infections in persons over the age of 50.
Bacteria Make Snow And Rain
Scientists in the US have discovered that living organisms like bacteria play an important role in making rain and snow in the atmosphere. The discovery could help researchers understand the role of living organisms in the water cycle and lead to better climate forecasting, and solve problems of water shortage, said the researchers.
Fact Sheet: HIV/AIDS among Persons Aged 50 and Over
The number of persons aged 50 years and older living with HIV/AIDS has been increasing in recent years. This increase is partly due to highly active antiretroviral therapy (HAART), which has made it possible for many HIV-infected persons to live longer, and partly due to newly diagnosed infections in persons over the age of 50.
Friday, February 29, 2008
Medtronic Announces First Human Use Of Its Bifurcation Stent
Medtronic Announces First Human Use Of Its Bifurcation Stent
Seeking to address a challenge facing interventional cardiologists and hundreds of thousands of patients with coronary artery disease worldwide, Medtronic, Inc. (NYSE: MDT), announced the first human use of its investigational bifurcation stent. The new stent employs an innovative Y-shaped design to match the anatomy of lesions that form at the junctions of coronary arteries. Dr.
Boston Scientific Announces First European Implants Of New Devices To Treat Heart Failure And Sudden Cardiac Death
Boston Scientific Corporation (NYSE: BSX) announced the first European implants of its COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable cardioverter defibrillator (ICD). Physicians began performing implants earlier this week. Forty implants have been performed in 14 hospitals in six countries. When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features.
FDA Approves Nexium For Use In Children Ages 1-11 Years
The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium in two forms, a delayed-release capsule and liquid form. Nexium is approved in 10 milligrams (mg) or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12 to 17 years of age.
Covidien Announces Tentative FDA Approval For Its Generic Myocardial Perfusion Imaging Kit
Covidien (NYSE: COV, BSX: COV) announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's tentatively approved product is a generic of Cardiolite�1, which is a myocardial perfusion imaging agent used for detecting coronary artery disease.
Broomwell's Cardiac Telemedicine Service Proven To Prevent Hospital Admissions In Year-Long Study
The results of a 12-month trial of a cardiac telemedicine service supervised by the Greater Manchester and Cheshire (GMC) Cardiac Network, has proven that the service avoids immediate referral of patients with non-acute chest-pain symptoms to hospital care, in nearly 60% of cases.
Seeking to address a challenge facing interventional cardiologists and hundreds of thousands of patients with coronary artery disease worldwide, Medtronic, Inc. (NYSE: MDT), announced the first human use of its investigational bifurcation stent. The new stent employs an innovative Y-shaped design to match the anatomy of lesions that form at the junctions of coronary arteries. Dr.
Boston Scientific Announces First European Implants Of New Devices To Treat Heart Failure And Sudden Cardiac Death
Boston Scientific Corporation (NYSE: BSX) announced the first European implants of its COGNIS(TM) cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN(TM) implantable cardioverter defibrillator (ICD). Physicians began performing implants earlier this week. Forty implants have been performed in 14 hospitals in six countries. When choosing a high-energy device, physicians often must make trade-offs among device size, battery longevity and features.
FDA Approves Nexium For Use In Children Ages 1-11 Years
The U.S. Food and Drug Administration approved Nexium (esomeprazole magnesium) for short-term use in children ages 1-11 years for the treatment of gastroesophageal reflux disease (GERD). The agency approved Nexium in two forms, a delayed-release capsule and liquid form. Nexium is approved in 10 milligrams (mg) or 20 mg daily for children 1-11 years old compared to 20 mg or 40 mg recommended for pediatric patients 12 to 17 years of age.
Covidien Announces Tentative FDA Approval For Its Generic Myocardial Perfusion Imaging Kit
Covidien (NYSE: COV, BSX: COV) announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) for its Kit for the Preparation of Technetium Tc 99m Sestamibi Injection. Covidien's tentatively approved product is a generic of Cardiolite�1, which is a myocardial perfusion imaging agent used for detecting coronary artery disease.
Broomwell's Cardiac Telemedicine Service Proven To Prevent Hospital Admissions In Year-Long Study
The results of a 12-month trial of a cardiac telemedicine service supervised by the Greater Manchester and Cheshire (GMC) Cardiac Network, has proven that the service avoids immediate referral of patients with non-acute chest-pain symptoms to hospital care, in nearly 60% of cases.
Subscribe to:
Posts (Atom)
